Silicon Valley Innovations

Silicon Valley Innovations (SVI) is a Silicon Valley-based biotech and medical device company focused on anatomically directed local drug delivery. The company has developed a patented platform, Anatomically Directed Drug Delivery™, for self-care and clinical care applications, initially targeting acute and chronic conditions in respiratory and feminine health. Founded by Dr. Gail Lebovic, SVI's flagship product, NasoClenz, a nasal cleansing kit, is already commercialized. Early clinical studies for NasoClenz demonstrated an 84% reduction in frequent and severe nasal symptoms for severe allergy sufferers, leading to significant commercial adoption with over 200% rolling 4-quarter average sales growth following its limited release in 2023. The company’s technology is designed to optimize medication delivery to specific anatomic sites to increase effectiveness and reduce systemic side effects, with products aimed at large markets like respiratory health ($71B) and feminine health ($21B). SVI plans to expand into additional anatomic sites and therapeutic areas, leveraging its platform technology for both prescription and over-the-counter use.